8-K: Sage Therapeutics' Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington's Disease

Sage Therapeutics' Phase 2 SURVEYOR study met its primary endpoint, demonstrating a statistically significant difference in cognitive function between healthy participants and those with Huntington's Disease.

Summary

• Sage Therapeutics announced positive topline results from its Phase 2 SURVEYOR study.
• The study focused on the cognitive impact of Huntington's Disease (HD) and the safety of dalzanemdor (SAGE-718).
• The primary endpoint was met, showing a statistically significant difference in cognitive scores between healthy participants and those with HD at baseline.
• The study enrolled 40 participants with HD and 29 healthy participants.
• The HD-Cognitive Assessment Battery (HD-CAB) was used to measure cognitive function.
• Participants with HD had a markedly lower baseline composite score (p < 0.0001) compared to healthy participants.
• In the second part of the study, participants with HD were randomly assigned to receive dalzanemdor or placebo for 28 days.
• Dalzanemdor was generally well-tolerated, with no new safety signals observed.
• There was a small numerical difference observed between dalzanemdor and placebo on the HD-CAB composite score at Day 28.
• The company plans to apply learnings from the SURVEYOR study to ongoing work on the dalzanemdor program.
• Topline data from the LIGHTWAVE study in Alzheimer's Disease and the DIMENSION study in HD are expected in late 2024.

Sentiment

Score: 7

Explanation: The document presents positive results from a Phase 2 study, indicating progress in the development of a potential treatment. However, the lack of statistical significance between the treatment and placebo groups in the second part of the study tempers the overall positive sentiment.

Positives

• The study successfully demonstrated the significant cognitive impairment associated with Huntington's Disease.
• Dalzanemdor was shown to be generally well-tolerated in participants with HD.
• The study provides valuable insights into the cognitive aspects of HD, which are often underrecognized.
• The results support the continued development of dalzanemdor as a potential treatment for cognitive impairment in HD.
• The company is advancing a clinical program for dalzanemdor with multiple ongoing Phase 2 studies.

Negatives

• The study was not designed or powered to demonstrate a statistically significant difference between dalzanemdor and placebo.
• The numerical difference observed between dalzanemdor and placebo on the HD-CAB composite score at Day 28 was small.
• The study was relatively small, with only 40 participants with HD.

Risks

• The results of ongoing clinical studies of dalzanemdor in HD and AD may be negative.
• Ongoing studies of dalzanemdor may not meet their primary or key secondary endpoints.
• Positive signals from earlier trials may not be replicated in ongoing or future trials.
• Clinical data may not be sufficient to move to the next phase of development.
• Adverse events could negatively impact further development.
• Delays in clinical trials or reporting of results could occur.
• Regulatory authorities may not agree with the company's view of the data.
• Even if approved, dalzanemdor may only be approved for a subset of the patient population.
• Technical hurdles in development and manufacturing could delay timelines.

Future Outlook

The company expects to report topline data from the LIGHTWAVE study in mild cognitive impairment and mild dementia in Alzheimer's Disease and the DIMENSION study in cognitive impairment associated with HD in late 2024.

Management Comments

• Laura Gault, Chief Medical Officer, stated that cognitive impairment is a historically underrecognized aspect of HD and there are no approved treatments for it.
• Laura Gault also mentioned that the findings from the SURVEYOR Study highlight the extent of cognitive impairment associated with HD and enhance our collective understanding of this devastating disease.

Industry Context

This announcement is significant as it addresses the unmet need for treatments for cognitive impairment in Huntington's Disease, a rare neurodegenerative condition. The positive results from the SURVEYOR study could position Sage Therapeutics as a leader in this therapeutic area.

Comparison to Industry Standards

• The study's focus on cognitive impairment in HD is notable, as many treatments primarily target motor symptoms.
• The use of the HD-CAB is a specific measure for cognitive assessment in HD, which is a positive step in the development of targeted therapies.
• While the study was not powered to show a statistically significant difference between dalzanemdor and placebo, the safety and tolerability data are encouraging.
• Other companies are also developing treatments for HD, but the focus on cognitive impairment is a differentiator for Sage Therapeutics.

Stakeholder Impact

• The positive results from the SURVEYOR study are encouraging for patients with Huntington's Disease and their families.
• The study results may positively impact investor confidence in Sage Therapeutics.
• The findings could lead to further research and development in the treatment of cognitive impairment in HD.

Next Steps

• The company plans to further analyze and understand the data from the SURVEYOR study.
• The company will apply relevant learnings to ongoing work on the dalzanemdor program.
• The company expects to report topline data from the LIGHTWAVE study in Alzheimer's Disease and the DIMENSION study in HD in late 2024.

Key Dates

Keywords

Huntington's Disease, dalzanemdor, SAGE-718, Cognitive Impairment, Neurodegenerative Disease, Clinical Trial, Phase 2 Study, HD-CAB, Alzheimer's Disease, NMDA receptor